Genmab A/S (GNMSF) Asset Writedowns and Impairment (2023 - 2026)

Genmab A (GNMSF) has 4 years of Asset Writedowns and Impairment data on file, last reported at $150.0 million in Q1 2026.

• Quarterly Asset Writedowns and Impairment rose 14900.0% year-over-year to $150.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $153.0 million (up 410.0% YoY) and the FY2025 annual result came in at $32.0 million, up 88.24% from the prior year.
• Asset Writedowns and Impairment rose to $150.0 million in Q1 2026, from $1.0 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $254.0 million in Q4 2023 to a low of $1.0 million in Q1 2025.
• A 4-year average of $54.5 million and a median of $9.0 million in 2024 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2025 — Asset Writedowns and Impairment plunged 90.91% — and 2026, when it surged 14900.0%.
• Tracing GNMSF's Asset Writedowns and Impairment over 4 years: stood at $254.0 million in 2023, then slumped by 95.67% to $11.0 million in 2024, then sank by 90.91% to $1.0 million in 2025, then surged by 14900.0% to $150.0 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at $150.0 million (Q1 2026), $1.0 million (Q3 2025), and $1.0 million (Q2 2025), per Business Quant data.